See today's BioWorld Science
To read the full story, subscribe or sign in.
Musculoskeletal

Rome Therapeutics raises new funds to advance LINE-1 reverse transcriptase inhibitor into clinic

Sep. 13, 2023
Rome Therapeutics Inc. has completed a $72 million series B extension financing, bringing the total series B amount raised to $149 million.
BioWorld Science Financings Inflammatory Musculoskeletal Series B